-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Blueprint Medicines (BPMC)
-
-
-
-
-
-
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Blueprint Medicines (BPMC)
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) PT Raised to $135 at Needham
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) PT Raised to $125 at Oppenheimer
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

